326 related articles for article (PubMed ID: 25422511)
21. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia.
Taipale H; Lähteenvuo M; Tanskanen A; Mittendorfer-Rutz E; Tiihonen J
Schizophr Bull; 2021 Jan; 47(1):23-30. PubMed ID: 33428766
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular aspects of antipsychotics.
Raedler TJ
Curr Opin Psychiatry; 2010 Nov; 23(6):574-81. PubMed ID: 20838345
[TBL] [Abstract][Full Text] [Related]
23. Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia.
Højlund M; Elliott AF; Madsen NJ; Viuff AG; Munk-Jørgensen P; Hjorth P
Nord J Psychiatry; 2017 Nov; 71(8):598-604. PubMed ID: 28836471
[TBL] [Abstract][Full Text] [Related]
24. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
25. Mortality and its determinants in people with psychotic disorder.
Suvisaari J; Partti K; Perälä J; Viertiö S; Saarni SE; Lönnqvist J; Saarni SI; Härkänen T
Psychosom Med; 2013 Jan; 75(1):60-7. PubMed ID: 23257931
[TBL] [Abstract][Full Text] [Related]
26. Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus.
Wu CS; Gau SS
Schizophr Bull; 2016 May; 42(3):703-11. PubMed ID: 26721264
[TBL] [Abstract][Full Text] [Related]
27. Disability Pension at the Time of Coronary Revascularisation Is Associated with Higher Five-Year Mortality; A Swedish Nationwide, Register-Based Prospective Cohort Study.
Zetterström K; Voss M; Alexanderson K; Ivert T; Pehrsson K; Hammar N; Vaez M
PLoS One; 2015; 10(8):e0135277. PubMed ID: 26261990
[TBL] [Abstract][Full Text] [Related]
28. Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment.
Zhai D; Cui T; Xu Y; Feng Y; Wang X; Yang Y; Li S; Zhou D; Dong G; Zhao Y; Yang Y; Zhang R
Schizophr Res; 2017 Jan; 179():41-49. PubMed ID: 27613506
[TBL] [Abstract][Full Text] [Related]
29. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
30. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study.
Fontanella CA; Campo JV; Phillips GS; Hiance-Steelesmith DL; Sweeney HA; Tam K; Lehrer D; Klein R; Hurst M
J Clin Psychiatry; 2016 May; 77(5):661-7. PubMed ID: 27249075
[TBL] [Abstract][Full Text] [Related]
31. Life expectancy and cardiovascular mortality in persons with schizophrenia.
Laursen TM; Munk-Olsen T; Vestergaard M
Curr Opin Psychiatry; 2012 Mar; 25(2):83-8. PubMed ID: 22249081
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.
Curkendall SM; Mo J; Glasser DB; Rose Stang M; Jones JK
J Clin Psychiatry; 2004 May; 65(5):715-20. PubMed ID: 15163261
[TBL] [Abstract][Full Text] [Related]
33. Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer's dementia.
Nielsen RE; Lolk A; M Rodrigo-Domingo ; Valentin JB; Andersen K
Eur Psychiatry; 2017 May; 42():14-23. PubMed ID: 28199869
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
[TBL] [Abstract][Full Text] [Related]
35. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study.
Westman J; Eriksson SV; Gissler M; Hällgren J; Prieto ML; Bobo WV; Frye MA; Erlinge D; Alfredsson L; Ösby U
Epidemiol Psychiatr Sci; 2018 Oct; 27(5):519-527. PubMed ID: 28580898
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study.
Laursen TM; Mortensen PB; MacCabe JH; Cohen D; Gasse C
Psychol Med; 2014 Jun; 44(8):1625-37. PubMed ID: 24246137
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J
BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203
[TBL] [Abstract][Full Text] [Related]
38. Excess mortality and cardiovascular events in patients surviving subarachnoid hemorrhage: a nationwide study in Sweden.
Nieuwkamp DJ; Algra A; Blomqvist P; Adami J; Buskens E; Koffijberg H; Rinkel GJ
Stroke; 2011 Apr; 42(4):902-7. PubMed ID: 21330628
[TBL] [Abstract][Full Text] [Related]
39. Multicity study of air pollution and mortality in Latin America (the ESCALA study).
Romieu I; Gouveia N; Cifuentes LA; de Leon AP; Junger W; Vera J; Strappa V; Hurtado-Díaz M; Miranda-Soberanis V; Rojas-Bracho L; Carbajal-Arroyo L; Tzintzun-Cervantes G;
Res Rep Health Eff Inst; 2012 Oct; (171):5-86. PubMed ID: 23311234
[TBL] [Abstract][Full Text] [Related]
40. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients.
Montout C; Casadebaig F; Lagnaoui R; Verdoux H; Philippe A; Begaud B; Moore N
Schizophr Res; 2002 Oct; 57(2-3):147-56. PubMed ID: 12223245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
